Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

NCT ID: NCT00070252

Last Updated: 2015-05-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 53 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-09-30
• Study Completion Date: 2010-06-30

Brief Summary

Phase I/II trial to study the effectiveness of neoadjuvant tipifarnib combined with docetaxel and capecitabine in treating patients who have locally advanced or metastatic solid tumors or stage IIIA or stage IIIB breast cancer. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy, such as docetaxel and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining tipifarnib with docetaxel and capecitabine may kill more tumor cells.

Detailed Description

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose and recommended dose of capecitabine in combination with docetaxel and tipifarnib in patients with locally advanced or metastatic solid tumors. (Phase Ib) II. Determine the complete pathological and clinical response rate in patients with stage IIIA or IIIB breast cancer treated with this regimen. (Phase II)

SECONDARY OBJECTIVES:

I. Determine the toxicity of this regimen in these patients. II. Determine disease-free and overall survival of patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of capecitabine. Patients in phase II are stratified according to type of breast cancer (inflammatory vs noninflammatory).

Phase Ib: Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14 and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Phase II: Patients receive oral tipifarnib twice daily for 6 days. Beginning at least 48 hours after completion of the initial dose of tipifarnib, patients receive treatment as in phase Ib for up to 6 courses at the MTD of capecitabine. Patients in phase Ib are followed at 3 months.

Patients in phase II are followed every 4 months for up to 5 years.

PROJECTED ACCRUAL: A total of 24-53 patients (9-18 for phase Ib and 15-35 for phase II) will be accrued for this study within 14-35 months.

Conditions

Adult Solid Neoplasm; Inflammatory Breast Carcinoma; Male Breast Carcinoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (tipifarnib, capecitabine, docetaxel)

Phase Ib: Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14 and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Phase II: Patients receive oral tipifarnib twice daily for 6 days. Beginning at least 48 hours after completion of the initial dose of tipifarnib, patients receive treatment as in phase Ib for up to 6 courses at the MTD of capecitabine.

Group Type: EXPERIMENTAL

Capecitabine

Intervention Type: DRUG

Given PO

Docetaxel

Intervention Type: DRUG

Given IV

Laboratory Biomarker Analysis

Intervention Type: OTHER

Correlative studies

Pharmacological Study

Intervention Type: OTHER

Correlative studies

Tipifarnib

Intervention Type: DRUG

Given orally (PO)

Interventions

Capecitabine

Given PO

Intervention Type: DRUG

Docetaxel

Given IV

Intervention Type: DRUG

Laboratory Biomarker Analysis

Correlative studies

Intervention Type: OTHER

Pharmacological Study

Correlative studies

Intervention Type: OTHER

Tipifarnib

Given orally (PO)

Intervention Type: DRUG

Other Intervention Names

Ro 09-1978/000; Xeloda; RP56976; Taxotere; Taxotere Injection Concentrate; R115777; Zarnestra

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed solid tumor

• Locally advanced or metastatic
• No known standard therapy that is potentially curative or definitely capable of extending life expectancy
• No history of metastatic brain disease within the past 6 months

• Treated metastatic brain disease is allowed provided disease has been stable for more than 6 months and does not require concurrent steroids or anti-seizure medication
• Histologically confirmed breast cancer

• Stage IIIA or stage IIIB, including ipsilateral palpable supraclavicular lymph node(s) without other distant metastasis
• Invasive disease confirmed by 1 of the following*:

• Incisional biopsy
• Punch biopsy (applicable for clinical T4b tumors)
• Core needle (cutting needle) biopsies
• No distant metastatic disease
• Hormone receptor status:

• Not specified
• Male or female
• Performance status - ECOG 0-1
• Absolute neutrophil count at least 2,000/mm^3
• Platelet count at least 100,000/mm^3
• Hemoglobin at least 10.0 g/dL
• Bilirubin no greater than upper limit of normal (ULN)
• Alkaline phosphatase no greater than 2.5 times ULN
• AST no greater than 2.5 times ULN
• Creatinine no greater than 1.25 times ULN
• Creatinine clearance at least 50 mL/min
• No cardiac arrhythmia
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active infection requiring antibiotics
• No diabetes
• No symptomatic neurologic condition
• No other uncontrolled serious medical condition
• No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• No history of hypersensitivity to intravenous paclitaxel or other medication containing Cremophor EL or polysorbate 80 as a carrier (phase Ib)
• Phase Ib only:

• More than 4 weeks since prior immunotherapy
• More than 4 weeks since prior biologic therapy
• No concurrent immunotherapy
• Phase Ib and II:

• No concurrent prophylactic filgrastim (G-CSF)
• Phase Ib only:

• More than 1 year since prior adjuvant docetaxel before metastatic relapse
• More than 4 weeks since prior chemotherapy and recovered
• No prior capecitabine AND docetaxel (in combination or as single agents)

• Prior capecitabine OR docetaxel allowed
• No other concurrent chemotherapy
• Phase II only:

• No prior cytotoxic chemotherapy for breast cancer
• Phase Ib only:

• More than 3 weeks since prior radiotherapy
• No prior radiotherapy to more than 25% of bone marrow
• No concurrent radiotherapy
• Phase II only:

• No prior radiotherapy for breast cancer
• Phase Ib only:

• More than 4 weeks since prior major surgery
• Phase II only:

• No prior surgery (other than core or incisional biopsy for diagnostic purposes) for breast cancer
• Phase Ib only:

• No other ancillary investigational therapy
• Phase Ib and II:

• No concurrent sorivudine or brivudine

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Philip Philip

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic in Arizona

Scottsdale, Arizona, United States

Howard University Cancer Center CCOP

Washington D.C., District of Columbia, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Washington University School of Medicine

St Louis, Missouri, United States

University of Wisconsin Medical School

Milwaukee, Wisconsin, United States

Countries

United States

Other Identifiers

NCI-2012-01442

Identifier Type: REGISTRY

Identifier Source: secondary_id

WSU-C-2679

Identifier Type: -

Identifier Source: secondary_id

MAYO-MC0131

Identifier Type: -

Identifier Source: secondary_id

NCI-5599

Identifier Type: -

Identifier Source: secondary_id

CDR0000331694

Identifier Type: -

Identifier Source: secondary_id

MC0131

Identifier Type: OTHER

Identifier Source: secondary_id

5599

Identifier Type: OTHER

Identifier Source: secondary_id

N01CM62205

Identifier Type: NIH

Identifier Source: secondary_id

View Link

P30CA015083

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NCI-2012-01442

Identifier Type: -

Identifier Source: org_study_id